Navigation Links
Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
Date:7/7/2009

products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1032 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
6. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
7. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
8. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
10. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
11. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 FemCap Inc., www.femcap.com  an ... receipt of a patent No: US, 8,795,248 B2 dated ... received FDA clearance in the U.S., 510(K) K121857, medical ... Europe. This patent is related to its menstrual cup with ... company is releasing FemmyCycle Teen, a third menstrual cup ...
(Date:9/30/2014)... SoundConnect, an award ... dedicated to supporting business communication solutions, including business ... a carrier services specialist has joined ... connected and productive at all times. This growth ... businesses to cloud communications services. On a ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Back in the ... 500 square feet. per employee, which included space for circulation ... then.” says Jeff Howell, partner at Nidea Corporate Real ... in Toronto. “By the year 2000, however, 250 square ... seeing that number come down to 175 to 225 square ...
(Date:9/29/2014)... 2014  Ten of the most highly-respected physicians ... regeneration, allograft reconstruction and research and development, as ... to discuss the future of cartilage regeneration at ... symposium, Cartilage Regeneration: State of the Art ... Minced Juvenile Allograft, and State of the Art ...
Breaking Biology Technology:The FemmyCycle 2SoundConnect Expands Carrier Services Division 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3
... DIEGO, Aug. 8 Halozyme Therapeutics, Inc.,(Nasdaq: ... targeting the extracellular matrix, today reported financial,results for ... 2008., "As we,ve previously stated, we continue ... programs that target large markets. Now we are,beginning ...
... -- China Sky One,Medical, Inc. ("China Sky One ... a,manufacturer, marketer and distributor of pharmaceutical, medicinal and,diagnostic ... conduct a,conference call at 10:00 a.m. Eastern Time ... 2008 financial results., Joining Mr. Yan-qing Liu, ...
... 8 Insmed Inc. (Nasdaq:,INSM), a developer of follow-on biologics and ... 30, 2008., Recent Company Highlights, -- Follow-on Biologics ... bioequivalence of INS-19, the ... factor (G-CSF), to Neupogen(R), an FDA-approved G-CSF product for ...
Cached Biology Technology:Halozyme Therapeutics Reports 2008 Second Quarter Financial Results 2Halozyme Therapeutics Reports 2008 Second Quarter Financial Results 3Halozyme Therapeutics Reports 2008 Second Quarter Financial Results 4Halozyme Therapeutics Reports 2008 Second Quarter Financial Results 5Halozyme Therapeutics Reports 2008 Second Quarter Financial Results 6Halozyme Therapeutics Reports 2008 Second Quarter Financial Results 7Halozyme Therapeutics Reports 2008 Second Quarter Financial Results 8Halozyme Therapeutics Reports 2008 Second Quarter Financial Results 9China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results 2China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results 3Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008 2Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008 3Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008 4Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008 5Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008 6Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008 7Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008 8Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008 9Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008 10
(Date:9/30/2014)... conducted by the Ocean Health Index rates the ... overall health. In addition, for the first time, ... ocean regions beyond national jurisdiction (high-seas areas) ... safeguarding biodiversity and providing sustainable food sources. , ... a partnership led by scientists from UC Santa ...
(Date:9/30/2014)... Ecker, a Salk professor and Howard Hughes Medical ... have been named recipients in the 2014 round ... (NIH) through the BRAIN (Brain Research through Advancing ... The grant, announced September 30, provides more than ... over three years. , The BRAIN Initiative, launched ...
(Date:9/30/2014)... almost any aquatic environment on Earth, but when the ... pushed to the limit. The amount of time needed ... how different species cope in the future, reveals a ... published in the scientific journal Proceedings of the ... thanks to increasing levels of greenhouse gases in the ...
Breaking Biology News(10 mins):Rating the planet's oceans 2Rating the planet's oceans 3Salk scientists receive $3 million for BRAIN Initiative grant 2Shape up quickly -- applies to fish, too! 2
... When neurons started dying in Clive Svendsen,s lab dishes, ... cells the same type lost in patients with ... that the University of Wisconsin-Madison stem cell biologist had ... lab, using stem cells derived from a patient. ...
... left Africa over 60,000 years ago in a migration that ... population that exist outside Africa today. Now, researchers ... that exodus. By tracing variations in the X chromosome and ... probably outnumbered women in that migration. The scientists expect that ...
... Deep inside the Frasassi cave system in Italy and more ... ropes of microbes growing in the cold water, according to ... microbiology paradise. Many different types of organisms live in the ... professor of geosciences. "We are trying to map which organisms ...
Cached Biology News:Patient-derived induced stem cells retain disease traits 2Patient-derived induced stem cells retain disease traits 3Unusual microbial ropes grow slowly in cave lake 2
...
... is the research-grade spectrofluorometer with a minimum ... S/N ratio 200 or greater for the ... especially designed to keep in mind in ... kinetics, stopped-flow, titration, or anisotropic measurements. ,The ...
... Microarrays designed for genome-wide microRNA expression ... and powerful Paraflo microfluidic on-chip synthesis ... part of our comprehensive microRNA Expression ... The Arabidopsis microRNA Microarray contains ...
... Microarrays designed for genome-wide microRNA expression profiling ... Paraflo microfluidic on-chip synthesis platform. These microarrays ... microRNA Expression Profiling Service. Probe ... all known cow microRNAs (108 unique mature ...
Biology Products: